Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 18/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.37 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633363 | 0.81 | CDK9 (0.50) | CDK9CCNT1 | |
| SCHEMBL26686523 | 0.81 | CDK9 (0.50) | CDK9CCNT1 | |
| SCHEMBL16041242 | 0.80 | CSF1R (0.52) | CDK9CCNT1 | |
| SCHEMBL3415636 | 0.79 | CDK9 (0.50) | CDK9CCNT1 | |
| SCHEMBL30380981 | 0.78 | CDK9 (0.52) | CDK9CCNT1 | |
| SCHEMBL3411433 | 0.78 | CDK9 (0.52) | CDK9CCNT1 | |
| SCHEMBL26686382 | 0.78 | CDK9 (0.54) | CDK9CCNT1 | |
| SCHEMBL26686464 | 0.76 | CDK9 (0.51) | CDK9CCNT1CDC7PIM1KMT5B | |
| SCHEMBL26888903 | 0.75 | GCK (0.41) | — | |
| SCHEMBL25427476 | 0.73 | CDK9 (0.63) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | CDK9 98/4885CCNT1 155/4885CDC7 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.